Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 10.50 +0.50 (+5.00%)
As of 07/15/2026 11:28 AM Eastern
Compare

CRTX vs. KAV, BZT, FAR, RMR, and GSP

Should you buy CRISM Therapeutics stock or one of its competitors? MarketBeat compares CRISM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISM Therapeutics include Kavango Resources (KAV), Bezant Resources (BZT), Ferro-Alloy Resources (FAR), Rome Resources (RMR), and Gensource Potash (GSP). These companies are all part of the "other industrial metals & mining" industry.

How does CRISM Therapeutics compare to Kavango Resources?

Kavango Resources (LON:KAV) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

CRISM Therapeutics has a net margin of 0.00% compared to Kavango Resources' net margin of -869.55%. Kavango Resources' return on equity of -68.85% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kavango Resources-869.55% -68.85% -14.06%
CRISM Therapeutics N/A -139.63%-26.77%

In the previous week, Kavango Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Kavango Resources Neutral
CRISM Therapeutics Neutral

Kavango Resources has a beta of 0.274, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, suggesting that its stock price is 40% less volatile than the broader market.

0.3% of CRISM Therapeutics shares are owned by institutional investors. 8.7% of Kavango Resources shares are owned by insiders. Comparatively, 50.5% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kavango Resources has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Kavango Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kavango Resources£1.72M16.59-£5.48K-£0.48N/A
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A

Summary

Kavango Resources beats CRISM Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to Bezant Resources?

CRISM Therapeutics (LON:CRTX) and Bezant Resources (LON:BZT) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

0.3% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 1.5% of Bezant Resources shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by insiders. Comparatively, 7.3% of Bezant Resources shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bezant Resources' return on equity of 21.18% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Bezant Resources N/A 21.18%-41.17%

In the previous week, Bezant Resources had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Bezant Resources and 0 mentions for CRISM Therapeutics. CRISM Therapeutics' average media sentiment score of 0.00 equaled Bezant Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Bezant Resources Neutral

CRISM Therapeutics has a beta of 0.599, indicating that its share price is 40% less volatile than the broader market. Comparatively, Bezant Resources has a beta of 0.852, indicating that its share price is 15% less volatile than the broader market.

Bezant Resources has lower revenue, but higher earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Bezant Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A
Bezant ResourcesN/AN/A-£8.40K£0.0115.73

Summary

Bezant Resources beats CRISM Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Ferro-Alloy Resources?

CRISM Therapeutics (LON:CRTX) and Ferro-Alloy Resources (LON:FAR) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

CRISM Therapeutics has a beta of 0.599, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Ferro-Alloy Resources has a beta of 0.841, meaning that its stock price is 16% less volatile than the broader market.

CRISM Therapeutics has a net margin of 0.00% compared to Ferro-Alloy Resources' net margin of -185.72%. Ferro-Alloy Resources' return on equity of 283.86% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Ferro-Alloy Resources -185.72%283.86%-21.47%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Ferro-Alloy Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Ferro-Alloy Resources Neutral

0.3% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Ferro-Alloy Resources shares are held by institutional investors. 50.5% of CRISM Therapeutics shares are held by company insiders. Comparatively, 47.1% of Ferro-Alloy Resources shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CRISM Therapeutics has higher earnings, but lower revenue than Ferro-Alloy Resources. Ferro-Alloy Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A
Ferro-Alloy Resources£4.53M5.75-£9.69M-£1.70N/A

Ferro-Alloy Resources has a consensus price target of GBX 30, suggesting a potential upside of 576.74%. Given Ferro-Alloy Resources' stronger consensus rating and higher probable upside, analysts clearly believe Ferro-Alloy Resources is more favorable than CRISM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ferro-Alloy Resources
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ferro-Alloy Resources beats CRISM Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CRISM Therapeutics compare to Rome Resources?

CRISM Therapeutics (LON:CRTX) and Rome Resources (LON:RMR) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

0.3% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Rome Resources shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by insiders. Comparatively, 16.6% of Rome Resources shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CRISM Therapeutics has a beta of 0.599, meaning that its share price is 40% less volatile than the broader market. Comparatively, Rome Resources has a beta of 0.015397686, meaning that its share price is 98% less volatile than the broader market.

Rome Resources' return on equity of -9.76% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Rome Resources N/A -9.76%-3.97%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Rome Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Rome Resources Neutral

Rome Resources has lower revenue, but higher earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Rome Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A
Rome ResourcesN/AN/AN/A-£2.04N/A

Summary

Rome Resources beats CRISM Therapeutics on 5 of the 8 factors compared between the two stocks.

How does CRISM Therapeutics compare to Gensource Potash?

CRISM Therapeutics (LON:CRTX) and Gensource Potash (LON:GSP) are both small-cap basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Gensource Potash's return on equity of -45.96% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Gensource Potash N/A -45.96%-10.31%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Gensource Potash'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Gensource Potash Neutral

CRISM Therapeutics has a beta of 0.599, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Gensource Potash has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

CRISM Therapeutics has higher revenue and earnings than Gensource Potash. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Gensource Potash, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A
Gensource PotashN/AN/A-£6.58M-£0.01N/A

0.3% of CRISM Therapeutics shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 6.2% of Gensource Potash shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CRISM Therapeutics beats Gensource Potash on 5 of the 9 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON Exchange
Market Cap£8.31M£1.47B£4.56B£2.77B
Dividend YieldN/A6.57%5.03%6.12%
P/E Ratio-2.0617.8720.93368.56
Price / Sales35.9953,824.156,468.9784,804.12
Price / CashN/A24.6326.5727.87
Price / Book0.245.498.787.77
Net Income-£792.20K£70.60M£157.11M£5.89B
7 Day Performance4.08%-1.37%-0.58%1.14%
1 Month Performance-4.55%-8.32%-5.69%-0.34%
1 Year Performance-9.40%66.90%39.03%62.94%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 10.50
+5.0%		N/A-2.8%£8.31M£231KN/A4
KAV
Kavango Resources
N/AGBX 0.65
-7.1%		N/A-40.5%£30.56M£1.72MN/A43
BZT
Bezant Resources
N/AGBX 0.15
+9.0%		N/A+211.1%£29.71MN/A16.295
FAR
Ferro-Alloy Resources
N/AGBX 4.49
-3.4%		GBX 30
+568.2%		-37.1%£27.33M£4.53MN/A1,000
RMR
Rome Resources
N/AGBX 0.33
+4.8%		N/A+14.8%£24.18MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
URGENT Dollar Reset Warning for Monday
A 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...
Golden Portfolio | Sponsoredtc pixel
What will Nvidia do next?
Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
BlackRock just moved $150 billion into this "new internet"
BlackRock CEO Larry Fink's 2026 chairman's letter compared tokenization to the birth of the internet - and the...
Awesomely, LLC | Sponsoredtc pixel
$30M Could Unlock $500M in Metal
A small exploration company is sitting on an estimated $500 million worth of antimony - a critical defense met...
i2i Marketing Group, LLC | Sponsoredtc pixel